Trial Profile
Clinical outcome with ceftazidime/avibactam in treatment of infections caused by multidrug-resistant Gram-negative organisms other than Klebsiella pneumoniae
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Sep 2018
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Bacterial infections
- Focus Therapeutic Use
- 11 Sep 2018 New trial record